Agentic AI buoys all stakeholders in oncology, with Eron Kelly

14 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
On the outskirts of the LSX conference in Boston last month, pharmaphorum EiC Jonah Comstock sat down with Eron Kelly, CEO of Concert AI, to discuss the work his Boston-based startup is doing in oncology.

ConcertAI offers a dual-facing product. CancerLinQ, acquired two years ago from ASCO, helps oncologists find clinical trials and identify treatment regiments for particular patients. Then ConcertAI sells data from CancerLinq to life sciences companies, along with an agentic AI suite to help them utilise that data across the business – from research to commercial.

Kelly discusses the ins and outs of making a business like his work, serving both the oncologists and the life sciences companies – and, ultimately, the patients. He discusses the importance of EHR integration and physician workflow and the flywheel effect the company relies on to grow its network.
Most interesting of all, Kelly talks about agentic AI and what it brings to the table for ConcertAI and its customers, describing the time savings AI agents can create across different use cases.

Learn more about ConcertAI in the video
Categoria
Oncology
Commenta per primo questo video.

Prossimo